A two-step strategy In the new work, Wyatt and his team first designed a mimic for the HIV spike protein—a key section of HIV's machinery that antibodies target to block infection. Unlike ...

Ohio State scientists engineered an antibody that may revolutionize prevention of the flu, other viruses and even non-viral diseases like cancer. The new molecule, delivered via nasal spray ...

The Boston-based company has developed an integrated AI and experimental platform to design de novo antibodies against particularly challenging disease targets, with an initial focus on ...

Pfizer is paying $1.25 billion upfront in a licensing pact with 3SBio, gaining access to the Chinese biotech’s PD-1/VEGF bispecific antibody for various solid tumors, the pharma revealed Monday ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Bispecific antibodies are a type of immunotherapy treatment which has generated responses across multiple clinical trials for patients with multiple myeloma, according to the International Myeloma ...

Mapping an antibody’s epitope, where it binds a target, can now be done in three dimensions, which optimizes the selection of application-specific antibodies When using antibodies in research or ...

Figure 1. BZN inhibits HNSCC cell proliferation, migration, and clonality. (A) CAL27 and FaDu cells were treated with varying concentrations of BZN (10, 15, 20, 25, 30, 35, 40, and 45 μM), TU177 and ...

Engineering antibodies with a novel fusion protein Fusing two immune system proteins leads to a new method of generating antibodies, opening opportunities for advancing drug discovery Date: March ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra ...

The Food and Drug Administration has approved more than 100 monoclonal antibodies to treat a range of diseases. Other antibodies are used by physicians to diagnose conditions or by scientists to ...

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. On a fourth-quarter earnings call with the media this morning ...